Pangenomic Health Inc. (NARA.CN)
CAD 0.14
(0.0%)
CAD 0.14
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.71 Million CAD | 25.26% |
| 2022 | -3.56 Million CAD | -326.51% |
| 2021 | -847.5 Thousand CAD | -521.17% |
| 2020 | -1808.00 CAD | -3968.63% |
| 2019 | -3366.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -228.33 Thousand CAD | -1189.56% |
| 2024 Q1 | -200.13 Thousand CAD | 63.07% |
| 2023 Q2 | -905.28 Thousand CAD | 13.8% |
| 2023 Q4 | -555.55 Thousand CAD | -49.97% |
| 2023 FY | - CAD | 19.3% |
| 2023 Q3 | -370.45 Thousand CAD | 59.08% |
| 2023 Q1 | -1.05 Million CAD | -4.4% |
| 2022 Q1 | -818.52 Thousand CAD | 65.74% |
| 2022 FY | - CAD | -326.51% |
| 2022 Q4 | -1 Million CAD | -0.65% |
| 2022 Q3 | -999.36 Thousand CAD | -24.26% |
| 2022 Q2 | -804.28 Thousand CAD | 1.74% |
| 2021 Q2 | -92.19 Thousand CAD | -32.93% |
| 2021 Q1 | -69.36 Thousand CAD | 48.68% |
| 2021 FY | - CAD | -521.17% |
| 2021 Q4 | -2.38 Million CAD | -1960.54% |
| 2021 Q3 | -115.94 Thousand CAD | -25.76% |
| 2020 FY | - CAD | -3968.63% |
| 2020 Q3 | -2150.00 CAD | 0.0% |
| 2020 Q4 | -135.15 Thousand CAD | -6186.05% |
| 2019 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AI/ML Innovations Inc. | -1.66 Million CAD | -62.88% |
| Diagnamed Holdings Corp. | -100.27 Thousand CAD | -2604.448% |
| nDatalyze Corp. | -290.5 Thousand CAD | -833.483% |
| Treatment.Com International Inc. | -3.64 Million CAD | 25.632% |
| Unidoc Health Corp. | -2.18 Million CAD | -24.228% |